After Successful Formulation Work, Cannabis Science Follows Through With a Full Clinical Drug Development Agreement With ImmunoClin to Deliver GMP Quality Pre-Clinical Data to Enter CS-NEURO-1 Into a Phase I Human Study in Europe


COLORADO SPRINGS, CO--(Marketwired - Dec 15, 2015) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced that it has entered into a comprehensive clinical drug development to focus on delivering GMP quality pre-clinical data to enable entry of CS-NEURO-1 into a Phase I human study in Europe with ImmunoClin (OTCQB: IMCL).

After ImmunoClin successfully completed its one-year formulation work for CBIS, focusing on cannabis extracts and cannabinoids, the results are compelling and conclusive. ImmunoClin will, under its class I license, initiate, manage, and coordinate all aspects of the new comprehensive clinical research program on behalf of Cannabis Science. The new program will focus on delivering compliant GMP quality pre-clinical data, including cultivation of CBIS specific cannabis strains, formulation and manufacturing of clinical grade material to enable entry of CS-NEURO-1 and other cannabinoid based products into a Phase I human studies in Europe.

"The formulation work we performed in the last year for Cannabis Science has allowed us to obtain a proof of concept with formulation of cannabinoids. We now anticipate moving rapidly into the pre-clinical development with animal and toxicity studies, permitting CBIS to prepare the package for Phase I human clinical trials in Europe," said Dr. Dorothy Bray, Ph.D., Director, President and CEO, ImmunoClin Corporation.

About ImmunoClin Corporation

ImmunoClin Corporation is a healthcare company with principal corporate office located in Washington, D.C., USA and European headquarters and laboratories in Central London, United Kingdom. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease. ImmunoClin holds multiple patents and trademarks on a global basis.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Contact Information:

Cannabis Science, Inc.
Investor Relations
Teresa Misenheimer
i-Business Management, LLC
Teresa@cannabisscience.com
Tel: 1.813.500.7332

Cannabis Science, Inc.
Mr. Raymond C. Dabney
Director, President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1.310.650.3788

ImmunoClin Corporation
Dr. Dorothy Bray
Director, President & CEO
www.immunoclin.com
dorothy.bray@immunoclin.com
Tel: 1.888.267.1175